Application
Research Sub CategoryImmunoglobulins & Immunology
Research CategoryInflammation & Immunology
Anti-EBI3 Antibody/IL-35, clone V1.4C4.22 (Neutralizing) is an antibody against EBI3 /IL-35 for use in Western Blotting, Neutralizing.
Neutralizing Analysis: A representative lot detected EBI3/IL-35 during in-vitro neutralizing (Collison, L.W., et al. (2010). Nat Immunol. 11(12):1093-1101).
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
EBI3/IL27B is the beta subunit of the functional cytokine IL-27. The beta subunit is required for activity. IL-27 is a critical cytokine of mammalian innate immune response. IL-27 has both pro and anti-inflammatory activities. IL-27 regulates T-helper cell development and differentiation into TH1, TH2 and TH17 effector cells. IL-27 also is important in isotype switching for B-cells, and it drives rapid clonal expansion of native but not memory CD4 cells. IL-27 is also important for its anti-tumor and anti-angiogenic activity on tumor and cancer cells. The beta subunit EBI3/IL27B is also a component of IL-35 which is a heterodimer of IL-12alpha and IL-27B/EBI3. IL-35 plays a role in immune suppression. IL-27 is a secreted cytokine, thus IL-27beta subunit is expressed intracellularly associated with the endoplasmic reticulum and membrane vesicles and is detected extracellularly as part of the mature cytokine as well.
Immunogen
Recombinant protein corresponding to mouse EBI3/IL-35.
Other Notes
Concentration: Please refer to lot specific datasheet.
Physical form
Protein G Purified
Format: Purified
Purified mouse monoclonal IgG2bκ in buffer containing PBS without preservatives.
Quality
Evaluated by Western Blotting in recombinant m-EBI3/IL-27.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected EBI3/IL-35 in 1 µg of recombinant m-EBI3/IL-27.
Specificity
Clone V1.4H6.25 (MABF836) was used in in-vitro mIL-35 neutralizing studies and clone V1.4C4.22 (MABF848) was used in in-vivo mIL-35 neutralizing studies (Collison, L.W., et al. (2010). Nat Immunol. 11(12):1093-1101).
Storage and Stability
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Target description
~25 kDa observed
This product has met the following criteria to qualify for the following awards: